Blood cancers

Second-generation BTK inhibitor balances efficacy and tolerability in relapsed, refractory CLL

Sponsored by AstraZeneca Pty Ltd

The rapid growth in treatment options for chronic lymphocytic leukaemia (CLL) is allowing clinicians to tailor treatment strategies in an attempt to balance efficacy with toxicity and tolerability considerations.1 The second-generation bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence) – developed to avoid off-target effects of earlier drugs in its class – is now available on ...

Already a member?

Login to keep reading.

© 2021 the limbic